Navigation Links
Calithera Biosciences Closes $40 Million in Series A Financing
Date:7/8/2010

h core technologies licensed from the University of California, San Francisco, to develop novel therapeutic approaches to the treatment of cancer.  The company is developing small molecules that directly activate caspases, the proteases responsible for initiating programmed cell death, or apoptosis, in cancer cells.  Calithera plans to develop activators of additional enzymes as therapeutic agents for the treatment of cancer and other proliferative diseases.  Located in South San Francisco, CA, Calithera Biosciences is privately held with backing from Morgenthaler Ventures, U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital.  For more information, please visit www.calithera.com.

UC Disclaimer

The information stated above was prepared by Calithera Biosciences and reflects solely the opinion of the company.  Nothing in this statement shall be construed to imply any support or endorsement of Calithera, or any of its products, by The Regents of the University of California, its officers, agents and employees.


'/>"/>
SOURCE Calithera Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
2. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. YM BioSciences raises US$3.2 million in support of JAK 1/2 program
7. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
8. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
9. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
10. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
11. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Follow us on ... nanomaterial with diameter ranging between 2 to 10 ... nanophotonics materials market. The unique electroluminescent, photoluminescent, photo-physical, ... quantum confinement effect render the nanoparticles versatile and ... scientific, technological, and commercial applications. A host of ...
(Date:5/6/2015)... 6, 2015  Oxis Biotech, Inc. (OXIS), a wholly ... announced today that Cassian Yee , M.D., Professor, ... at the University of Texas MD Anderson Cancer Center ... Professor, Department of Immunology, Division of Cancer Medicine, and ... Research at the University of Texas MD Anderson Cancer ...
(Date:5/6/2015)... 2015 Dr Jaspreet Singh , Senior ... deliver a speech at the 2015 Asian Starch Conference, to ... Expo Center.  , ... the topic: ,Potato Starch: A Potential Source for the ... Co-editor of a 528 page text book entitled ...
(Date:5/5/2015)... SAN DIEGO AND TORONTO, May 5, 2015 /PRNewswire/ - Aptose ... "Company") today reported financial results for the three months ... Unless specified otherwise, all amounts are in Canadian dollars. ... changed its fiscal year end from May 31 to ... current interim period being reported is for the three ...
Breaking Biology Technology:Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 2Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 3Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8
... ... ensure future crisis prevented. , ... Davos-Klosters, Switzerland (Vocus) Jan. 29, 2010 -- Agriculture is a game-changer that ... such as civil unrest, DuPont Chair and CEO Ellen Kullman told attendees ...
... , Data Demonstrating a 35% Overall Response ... in Patients with Relapsed or Relapsed/Refractory Waldenstrom,s Macroglobulinemia to ... Issue of the Journal of Clinical Cancer Research , ... Zentaris Inc. (Nasdaq: AEZS ; TSX: AEZ) (the ...
... , Jan. 28 RSB Spine, LLC, today ... the company,s 510(k) application to permit the marketing of its ... Executive Officer John A. Redmond said: "We are ... distributors two additional products to offer customers seeking greater options ...
Cached Biology Technology:DuPont Chair and CEO: Agriculture is Key to Global Economic Growth, Sustainability and Security 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 3Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 4Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 5
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... , April 2, 2015 Fingerprint ... fingerprint sensor FPC1025 from the distributor World Peace Industrial ... during Q2 2015 although the major part of the ... will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... across the United States and Russia are departing July 2 ... program, known as The Polaris Project, is training future leaders ... the impacts of climate change. Dr. R. ... Center and director of the Polaris Project, says, "The Arctic ...
... researchers have been able to identify genetic predictors of the ... Cathy Allen, from the Rotunda Hospital, Dublin, Ireland, told the ... and Embryology today (Wednesday 1 July) that her research would ... for others. Previous work in this area has looked ...
... of forest biotechnology to help address significant social and ... rigid opposition of some groups and regulations that effectively ... argue in a new report. Steps must be ... modified trees on a scientific, case-by-case basis, and is ...
Cached Biology News:International team of students and scientists on month-long field course in Siberian Arctic 2International team of students and scientists on month-long field course in Siberian Arctic 3Will IVF work for a particular patient? The answer may be found in her blood 2Will IVF work for a particular patient? The answer may be found in her blood 3Anti-biotech groups obstruct forest biotechnology 2Anti-biotech groups obstruct forest biotechnology 3